- (PLX AI) - Bavarian Nordic's deal with Nuance Pharma to develop and sell the RSV vaccine in China and other Asian markets is a positive surprise, analysts at Carnegie said.
- • RSV deals were not expected until next year, according to Carnegie, and this agreement could add more than 5% to Bavarian's valuation, the analysts said
- • Shares rose 2.4%
- • A global partnership deal for the RSV vaccine is still expected during the second half of next year, and this agreement in China should not negatively impact that, the analysts said
© 2022 PLX AI
